BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

在国内，可切除胰腺癌的术后辅助化疗方案推荐以吉西他滨或氟尿嘧啶类药物（5-FU、吉西他滨或替吉奥）为基础的治疗方案。对于体能状态良好的胰腺癌患者，指南推荐进行联合化疗，包括吉西他滨 + 卡培他滨、mFOLFIRINOX 方案等。对于体能状态较差的患者 ...

Getting a second opinion made all the difference for a River Forest man—who was found to have pancreatic cancer, but is now ...

Key eligibility criteria were patients age 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas. Country of participation and resection margin ...

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the ...

The following is a summary of “An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal ...

Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing ...

The trial also met its primary safety endpoint. Treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) in the elraglusib-GnP combination arm were similar to those observed in the ...

USA News Group News Commentary – Immunotherapy is revolutionizing oncology by harnessing the power of the immune system to ...